NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers
NRG1 fusion positivity has gained interest as a treatment target in lung and pancreatic cancer, leading to the FDA approval of zenocutuzumab in December 2024.
Related Articles
Best of 2024: Top Features From Cancer Therapy Advisor
This page includes links to Cancer Therapy Advisor’s top feature articles published in 2024.
Mount Sinai Researchers Identify Six-Gene Pattern to Predict Drug Success in Multiple Myeloma Patients
Genetic markers for venetoclax could help personalize treatment and improve outcomes
Registration
Registration details for AACR IO: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy
Navigating the Blood Cancer Journey: What Everyone Should Know
Victor Gonzalez of The Lymphoma Research Foundation talks hope, mindfulness, identity, and treatment.
AACR Distinguished Lectureship recipient offers insight into invasive lobular carcinoma research – SABCS Meeting News
Steffi Oesterreich, PhD, on Thursday shared highlights from her seminal fundamental and translational research on invasive lobular carcinoma.
How the 2024 elections can impact cancer policy – The Cancer Letter
As we come within a stone’s throw of Nov. 5, we can’t help but wonder if and how the election outcome will impact health care…
AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients
Discover emerging themes and early-stage clinical oncology pipelines at the second AACR Oncology Industry Partnership event.
January 2025 – OCE ENGAGE – Project Community
Click to share this newsletter with your friends! Welcome to the January 2025 edition of the FDA Oncology Center of Excellence (OCE) quarterly newsletter from…
SSO President Update: ACT 2025 with Dr. Senthil
Watch this latest SSO President Update featuring Maheswari Senthil, MD, discussing details of the upcoming Advanced Cancer Therapies meeting taking place in …
Bortezomib combined with ibrutinib/rituximab in the first-line treatment of WM
Christian Buske, MD, University Hospital Ulm, Ulm, Germany, discusses findings from the ECWM-2 trial (NCT03620903), which evaluated the combination of ibrutinib, rituximab, and bortezomib for…
